Aurora Therapeutics — cofounded and advised by gene‑editing pioneers including Jennifer Doudna and Fyodor Urnov — launched with seed backing to scale bespoke CRISPR therapies for ultra‑rare mutations. The Menlo Ventures‑backed startup plans to group multiple variants under unified development pathways that leverage the FDA’s emerging 'plausible mechanism' regulatory options for personalized edits. Aurora’s initial focus includes phenylketonuria (PKU) where heterogeneous PAH mutations present a use case for a grouped, adaptable editing platform. Company founders cite preclinical proof‑of‑concept and regulatory engagement as rationale to pursue a scalable model for single‑patient and small‑cohort CRISPR interventions.